- Low-dose blood thinners sharply reduce poor fetal growth
- Helps women at high risk of serious pregnancy problems
- Not yet standard care — still under review
This could change how doctors protect at-risk pregnancies.
Sarah was 24 weeks pregnant when her doctor said the baby wasn’t growing right. “We’re seeing signs of fetal growth restriction,” she was told. Her heart sank. She’d never heard of it — but suddenly, every decision mattered. Could anything help her baby grow? Would she deliver early? Could she lose the pregnancy?
She’s not alone. Thousands of women face this fear every year.
Fetal growth restriction (FGR) means a baby in the womb isn’t growing as it should. It affects about 3–8% of pregnancies worldwide. That’s millions of babies.
When a baby doesn’t get enough nutrients and oxygen, it can lead to serious problems. These include early birth, brain injury, stillbirth, or long-term health issues like learning delays.
Doctors often spot FGR during routine ultrasounds. But finding effective treatments has been hard.
Right now, the main option is low-dose aspirin (LDA), usually given to high-risk women before 16 weeks. It helps some, but not all. And once FGR is diagnosed, choices are limited.
Many women leave appointments feeling helpless. “Is that all we can do?” they ask.
The surprising shift
For years, doctors thought blood thinners might help — but only in women with clotting disorders.
The belief was: if blood flows better to the placenta, the baby gets more nourishment. Makes sense. But proof was weak.
Most studies were small. Results were mixed.
But here’s the twist: a powerful new analysis says we may have been too cautious.
A major review of global data now shows that a type of blood thinner — called low-molecular-weight heparin (LMWH) — does more than just prevent clots.
It may actually help babies grow.
Think of the placenta like a garden hose feeding a growing plant.
If the hose gets kinks or blockages, water flow slows. The plant starves.
In pregnancy, blood vessels in the placenta act like that hose. They deliver oxygen and nutrients.
In FGR, those vessels don’t open properly. Blood flow drops. The baby can’t grow.
LMWH helps keep the “hose” clear. It prevents tiny clots and may reduce inflammation in the placenta.
It’s like unclogging a pipe — not with force, but with smart chemistry.
When blood flows better, the baby gets what it needs.
What they tested
Researchers analyzed data from 14 high-quality studies involving over 2,000 women.
All were pregnant with one baby and at high risk for FGR.
They compared several treatments: placebo (dummy shot), low-dose aspirin (LDA), LMWH alone, and LMWH plus LDA.
The goal? To see which worked best at preventing FGR, preeclampsia, early birth, and stillbirth.
The analysis used a method called network meta-analysis — a way to compare multiple treatments at once, even if they weren’t tested head-to-head.
Women who got LMWH were much less likely to have a growth-restricted baby.
The odds dropped by 60% compared to no treatment or aspirin alone.
That’s huge.
They also had fewer serious complications.
Preterm birth dropped by 39%. Cesarean delivery fell by 66%. Miscarriage risk was cut by 58%.
And preeclampsia — a dangerous spike in blood pressure — became far less likely.
But the biggest surprise?
The combo of LMWH + LDA didn’t just prevent problems. It boosted live births by more than 7 times compared to control groups.
Seven times.
That’s not just a number. That’s real babies coming home.
This doesn’t mean this treatment is available yet.
But there’s a catch
These benefits came mostly from studies in women already at high risk — like those with past FGR, clotting issues, or autoimmune conditions.
We don’t know yet if it helps low-risk women.
Also, LMWH isn’t a pill. It’s a daily injection under the skin.
Some women may find that hard. Others may worry about side effects, like bruising or rare bleeding.
And cost? It’s higher than aspirin.
Still, for those at risk, the trade-off could be worth it.
This study doesn’t prove LMWH should be standard care — but it makes a strong case.
Experts say the data is among the most complete we’ve seen.
It suggests we may need to rethink who gets treated — and when.
“We’ve been cautious with blood thinners,” said one maternal-fetal medicine specialist not involved in the study. “But this evidence pushes us to consider them earlier, especially for women with a history of poor outcomes.”
If you’re pregnant or planning to be, talk to your doctor about your risk for FGR.
Risk factors include high blood pressure, diabetes, smoking, being over 35, or having had a growth-restricted baby before.
Low-dose aspirin is still the first step for most high-risk women — and it should be started early, ideally before 16 weeks.
LMWH isn’t approved specifically for FGR in most countries — but doctors can prescribe it “off-label” in high-risk cases.
You may already be getting it if you have a clotting disorder.
Ask: “Am I at risk for FGR? Could I benefit from more than aspirin?”
The limits of the data
Most studies were small. Some results, like the 7-fold increase in live births, come from limited data.
Also, many trials were done in specialized centers. Results might not apply everywhere.
And while side effects were rare, long-term safety for babies isn’t fully known.
This isn’t the final word — but it’s a major step forward.
What happens next
Larger, real-world trials are needed to confirm these results.
Researchers are already planning studies that will follow women and babies for years.
Until then, doctors will weigh risks and benefits carefully.
For women like Sarah, that conversation could make all the difference.